Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NSABP B-30: Adjuvant AC-T vs AT vs ATC in Node-Positive Breast Cancer
NCT00003782Phase 3Completed
- Sponsor
- NSABP Foundation
- Start
- Mar 1999
- Primary completion
- Dec 2008
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of docetaxel, pegylated liposomal doxorubicin and cyclophosphamide in breast cancer (3 arms), sponsored by NSABP Foundation. Primary endpoints: Overall Survival at 8 years and Disease Free Survival. Started Mar 1999; status: completed.
02
Drugs
docetaxelpegylated liposomal doxorubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00003782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003782.